Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun.319:1281–1286. [DOI] [PubMed] [Google Scholar] · DOI
Cited by
Items 501–600 of 954
Emerging drugs for schizophrenia
Biedermann, F., & Fleischhacker, W. W. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.556112 · Cited by 26
“This suggests that NMDA system hypofunction may be part of schizophrenia pathophysiology [13].”
BackgroundRogóż, Z., Kamińska, K., Lech, M. A., & Lorenc‐Koci, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042125 · Cited by 22
“Therefore, it is debatable whether the transient inhibition of GSH synthesis by BSO during early postnatal development leads to hypo- or hyperfunction of glutamatergic transmission in specific brain structures of adult Sprague-Dawley rats, especially in the PFC, in which both an increase and a decrease in glutamatergi…”
BackgroundYang, S. M., Ghoshal, A., Hubbard, J. M., Gackière, F., Teyssié, R., Neale, S. A., Hopkins, S. C., Koblan, K. S., Bristow, L. J., & Dedic, N. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01779-x · Cited by 21
“Maintenance of the balance of excitatory and inhibitory signals is critical for the function of neural networks, and disruption of this fi nely tuned E/I balance has been proposed as part of a circuit-level mechanism for schizophrenia [6, 7, 52].”
BackgroundMETABOLIC SYNDROME AND PSYCHIATRIC ILLNESS
Mendelson, S. D. (2008) · Elsevier eBooks · doi:10.1016/b978-012374240-7.50006-1 · Cited by 22
Hasan, A., Bergener, T., Nitsche, M. A., Strube, W., Bunse, T., Falkai, P., & Wobrock, T. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00121 · Cited by 27
Strube, W., Bunse, T., Nitsche, M. A., Palm, U., Falkai, P., & Hasan, A. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.027 · Cited by 22
Involvement of Glutamate in Learning and Memory
Gasbarri, A., & Pompili, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-408139-0.00004-3 · Cited by 27
Current Understanding of the Role of Neuronal Calcium Sensor 1 in Neurological Disorders
Bandura, J., & Feng, Z. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1497-2 · Cited by 23
Adenosine Kinase Expression in the Frontal Cortex in Schizophrenia
Moody, C. L., Funk, A. J., Devine, E. A., Homan, R., Boison, D., McCullumsmith, R. E., & O'Donovan, S. M. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sbz086 · Cited by 21
Dixon, B. J., Kumar, J., & Danielmeier, C. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.010 · Cited by 23
“This could result in differences in the severity of symptoms between chronic patients who have lived with the condition for a prolonged period of time, and patients exhibiting symptoms for the first time (Coyle, 2006; Dauvermann et al., 2017).”
Backgroundde Oliveira, R. P., Nagaishi, K. Y., & Silva, R. C. B. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.01.053 · Cited by 21
Annes, W. F., Long, A. J., Witcher, J., Ayan‐Oshodi, M., Knadler, M. P., Zhang, W., Mitchell, M. I., Cornelissen, K., & Hall, S. D. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24226 · Cited by 21
Handbook of neurochemistry and molecular neurobiology, schizophrenia
Lajtha, Á., Javitt, D. C., & Kantrowitz, J. T. (2009) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · doi:10.1007/978-0-387-30410-6 · Cited by 23
Taber, K. H., & Hurley, R. A. (2008) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20.2.iv · Cited by 23
Calcyon upregulation in adolescence impairs response inhibition and working memory in adulthood
Vazdarjanova, A., Bunting, K., Muthusamy, N., & Bergson, C. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.14 · Cited by 20
Archer, T., & Kostrzewa, R. M. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9543-y · Cited by 21
Protein interacting with C kinase and neurological disorders
Focant, M. C., & Hermans, E. (2013) · Synapse · doi:10.1002/syn.21657 · Cited by 22
Marriott, A. L., Ryan, C. L., & Doucette, T. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.022 · Cited by 23
“…of schizophrenia is the result of an altered interaction between glutamate (Glu) and dopamine (DA) systems, with one of the most common theories being that hypofunction of the Glu system (particularly within the prefrontal cortex) results in hyperactivity of the mesolimbic DA neurons (Coyle, 2006).”
Behrendt, R. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.07.009 · Cited by 20
Investigational dopamine antagonists for the treatment of schizophrenia
Wang, S., Han, C., Lee, S.-J., Jun, T., Patkar, A. A., Masand, P. S., & Pae, C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1323870 · Cited by 22
Bases neurobiológicas de la Esquizofrenia
Jerónimo, S. R., de la Vega Sanchez Diego, C., & Patricia, S. P. (2010) · Clínica y Salud · doi:10.5093/cl2010v21n3a3 · Cited by 59
Gao, X., Grendel, J., Muhia, M., Castro‐Gomez, S., Süsens, U., Isbrandt, D., Kneussel, M., Kuhl, D., & Ohana, O. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0623-19.2019 · Cited by 23
“In the absence of other dopaminergic or behavioral abnormalities, we speculate that the transient amphetamine response reflects direct or circuit-level modifications in serotonergic, adrenergic (van den Buuse et al., 2011; Schmidt and Weinshenker, 2014), or glutamatergic transmission (Coyle, 2006).”
BackgroundRoméo, B., Petillion, A., Martelli, C., & Benyamina, A. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.03.006 · Cited by 21
Investigating cortical excitability and inhibition in patients with schizophrenia: A TMS-EEG study
Santoro, V., Hou, M. D., Premoli, I., Belardinelli, P., Biondi, A., Carobin, A., Puledda, F., Michalopoulou, P. G., Richardson, M. P., Rocchi, L., et al. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110972 · Cited by 20
“…synaptic GABAAergic inhibition may contribute to the reduction of early theta TRSP, as positive modulation of GABAA receptors with GABA-modulating drugs has been found to increase theta oscillatory power in the rat motor cortex in vitro (Berretta et al., 2004; Coyle, 2006; Gisabella et al., 2005).”
BackgroundEgis-11150: A candidate antipsychotic compound with procognitive efficacy in rodents
Gacsályi, I., Nagy, K. E., Pallagi, K., Lévay, G. I., Hársing, L. G., Móricz, K., Kertész, S., Varga, P., Haller, J., Gigler, G., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.017 · Cited by 22
“…appeared substantially more potent, which raises the possibility that it interactswith additional receptors, suchas those for GABA or glutamate, which have been widely implicated the pathogenesis of psychotic conditions (Benes and Berretta, 2001; Blum and Mann, 2002; Coyle, 2006; Tamminga,1999).”
BackgroundZhou, X., Chen, Q., Hu, X., Mao, S., & Kong, Y. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.10.025 · Cited by 19
Irimia, C., Buczynski, M. W., Natividad, L. A., Laredo, S. A., Avalos, L. N., & Parsons, L. H. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.2466-16.2017 · Cited by 19
“As a coagonist, glycine may improve response inhibition by reversing hypofunctioning states of the NMDA receptor (Coyle, 2006).”
BackgroundUpdate Anti-N-Methyl-D-Aspartat-Rezeptor-Enzephalitis
Kovac, S., Alferink, J., Ahmetspahic, D., Arolt, V., & Melzer, N. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0405-0 · Cited by 22
Kubíčková, B., Ramwell, C., Hilscherová, K., & Jacobs, M. N. (2021) · Environmental Sciences Europe · doi:10.1186/s12302-020-00428-0 · Cited by 22
Gamma Power and Cognition in Patients with Schizophrenia and Their First-Degree Relatives
Díez, Á., Suazo, V., Casado, P., Martín‐Loeches, M., & Molina, V. (2014) · Neuropsychobiology · doi:10.1159/000356970 · Cited by 20
Arco, A. D., Ronzoni, G., & Mora, F. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2055-9 · Cited by 22
“…in both humans and experimental animals have suggested that some neurophysiological and behavioural abnormalities found in schizophrenic patients can be correlated with a dysfunction of NMDA receptors (Javitt and Zukin 1991; Breier et al. 1997; Jentsch and Roth 1999; Lahti et al. 2001; Coyle 2006).”
BackgroundInfluentialChung, J. W., Seo, J.-H., Baek, S.-B., Kim, C., & Kim, T.-W. (2014) · Journal of Exercise Rehabilitation · doi:10.12965/jer.140144 · Cited by 19
“Abnormal expression of N-methyl-D-aspartate (NMDA) receptor, one of the glutamate receptor subtypes, has also been suggested to contribute to the symptoms of schizophrenia (Coyle, 2006).”
BackgroundUsing rodents to model schizophrenia and substance use comorbidity
Ng, E., McGirr, A., Wong, A. H. C., & Roder, J. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.03.025 · Cited by 21
Docherty, A. R., Bigdeli, T. B., Edwards, A. C., Bacanu, S., Lee, D., Neale, M. C., Wormley, B., Walsh, D., O’Neill, F. A., Riley, B. P., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.02.013 · Cited by 20
“The glutamate hypothesis of SCZ has been widely discussed (for a review, see Coyle, 2006) and it has been noted that drugs affecting glutamatergic transmission via NMDA receptor function have an influence on negative and cognitive symptoms of SCZ.”
Čiháková, D., Eaton, W. W., Talor, M. V., Harkus, U. H., Demyanovich, H. K., Rodriguez, K. M., Feldman, S. M., & Kelly, D. L. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.01.007 · Cited by 19
“Clinician Knows Best”? Injustices in the Medicalization of Mental Illness
Gosselin, A. (2019) · Feminist Philosophy Quarterly · doi:10.5206/fpq/2019.2.7285 · Cited by 22
Zahid, U., McCutcheon, R. A., Borgan, F., Jauhar, S., Pepper, F., Nour, M. M., Rogdaki, M., Osugo, M., Murray, G. K., Hathway, P., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.967941 · Cited by 19
Scoriels, L., Salek, R. M., Goodby, E., Grainger, D. J., Dean, A. M., West, J. A., Griffin, J. L., Suckling, J., Nathan, P. J., Lennox, B., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.26 · Cited by 19
Sapkota, K., Irvine, M. W., Fang, G., Burnell, E. S., Bannister, N. J., Volianskis, A., Culley, G. R., Dravid, S. M., Collingridge, G. L., Jane, D. E., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.007 · Cited by 18
“…diseases (Kamat et al., 2016; Koutsilieri and Riederer, 2007; Pivovarova and Andrews, 2010), whereas too little NMDAR activity impairs CNS function and, in particular, may cause symptoms seen in schizophrenia and autism (Coyle, 2006; Kantrowitz and Javitt, 2010; Lisman et al., 2008).”
BackgroundPalmer, C. J., Ellis, K. A., O’Neill, B. V., Croft, R. J., Leung, S., Oliver, C., Wesnes, K. A., & Nathan, P. J. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.904 · Cited by 18
Spiros, Ä., Roberts, P., & Geerts, H. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00229 · Cited by 18
“Schizophrenia pathology in the cortical network is introduced as a reduction in glutamate tone (Coyle, 2006), decreased dopamine tone (Meyer-Lindenberg et al., 2002; Weinberger, 2007) in the cortex, impaired GABA physiology through a decrease in GAD67 activity resulting in lower GABA release…”
BackgroundMethodYang, Y., Yuan, C., Shen, S., Wang, X.-E., Mei, Q., Jiang, W.-Q., & Huang, Q. (2017) · Mediators of Inflammation · doi:10.1155/2017/5047898 · Cited by 18
Understanding the role of thalamic circuits in schizophrenia neuropathology
Anticevic, A. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.044 · Cited by 18
Ahnaou, A., Biermans, R., & Drinkenburg, W. H. I. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147365 · Cited by 18
“On the other hand, pharmacological, anatomical and genetic studies indicate that deficits in glutamatergic neurotransmission contribute to all symptoms of schizophrenia [44,45].”
BackgroundSuga, M., Nishimura, Y., Kawakubo, Y., Yumoto, M., & Kasai, K. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12397 · Cited by 17
Austen, J. M., Sprengel, R., & Sanderson, D. J. (2017) · Scientific Reports · doi:10.1038/s41598-017-07542-9 · Cited by 19
Tarrés-Gatius, M., López‐Hill, X., Miquel-Rio, L., Castarlenas, L., Fabius, S., Santana, N., Vilaró, M. T., Artigas, F., Scorza, C., & Castañé, A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109079 · Cited by 17
Horiguchi, M., Miyauchi, M., Neugebauer, N. M., Oyamada, Y., & Meltzer, H. Y. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.08.040 · Cited by 17
Okuda, H., Kuwahara, R., Matsuzaki, S., Miyata, S., Kumamoto, N., Hattori, T., Shimizu, S., Yamada, K., Kawamoto, K., Hashimoto, R., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008773 · Cited by 19
“The etiology of the disease remains unknown, but in recent years a convergence of genetic, pharmacological, and neuroanatomical findings suggest that neural transmission [1–4] and synapse formation [5–11] are involved in schizophrenia.”
BackgroundRawas, R. E., Saadé, N. E., Thiriet, N., Atweh, S., Jaber, M., & Al-Amin, H. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.009 · Cited by 17
“Data from animal models and postmortem neurochemical studies have also implicated the NMDA receptors and the glutamate system in the neurobiology of schizophrenia (Coyle, 2006; Kristiansen et al., 2007; Morris et al., 2005; Mouri et al., 2007; Shim et al., 2008).”
ResultAmberg, W., Lange, U. E. W., Ochse, M., Pohlki, F., Behl, B., Relo, A. L., Hornberger, W., Hoft, C., Mezler, M., Sydor, J. R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00300 · Cited by 17
Thomsen, M. S., Hansen, H. H., & Mikkelsen, J. D. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.10.011 · Cited by 19
Djurovic, S., Kähler, A. K., Kulle, B., Jönsson, E. G., Agartz, I., Hellard, S. L., Hall, H., Jakobsen, K. D., Hansen, T. F., Melle, I. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.010 · Cited by 20
“Several lines of evidence implicate the glutamate system in the pathogenesis of schizophrenia, including a series of results from clinical, brain imaging, post mortem and animal studies (Coyle, 2006).”
Ward, K. R., Featherstone, R. E., Naschek, M. J., Melnychenko, O., Banerjee, A., Yi, J., Gifford, R. L., Borgmann‐Winter, K. E., Salter, M. W., Hahn, C.-G., et al. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.02.017 · Cited by 19
“Pre-clinical and clinical studies suggest that there is a strong link between N-methyl-D-aspartate receptor (NMDAR) hypofunction and pathophysiologies seen in schizophrenia and related disorders (Coyle, 2006; Jentsch and Roth, 1999; Lahti et al., 1995; Lahti et al., 2001; Milenkovic et al., 2014).”
BackgroundSociality deficits in serine racemase knockout mice
Matveeva, T. M., Pisansky, M. T., Young, A., Miller, R. F., & Gewirtz, J. C. (2019) · Brain and Behavior · doi:10.1002/brb3.1383 · Cited by 17
“…em‐ phasis in efforts to elucidate this disease's underlying pathophysi‐ ology (Abi‐Saab, D'Souza, Moghaddam, & Krystal, 1998; Anand et al., 2000; Coyle, 2006; Gaisler‐Salomon, Diamant, Rubin, & Weiner, 2007; Lahti, Koffel, LaPorte, & Tamminga, 1995; Lahti, Weiler, Tamara Michaelidis,…”
Novel Therapeutics for Schizophrenia: Targeting Glycine Modulation of NMDA Glutamate Receptors
Stahl, S. M. (2007) · CNS Spectrums · doi:10.1017/s1092852900015297 · Cited by 17
Nitric Oxide and Symptom Reduction in Schizophrenia
Coyle, J. T. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.210 · Cited by 17
Self-citationO’Tuathaigh, C. M. P., Desbonnet, L., & Waddington, J. L. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.08.009 · Cited by 18
“Psychopharmacological studies conducted in humans and rodents have shown that the NMDA receptor antagonists phencyclidine and ketamine induce a wide spectrum of schizophrenia-like features, including positive, negative and cognitive symptoms (Kegeles et al., 2000; Coyle, 2006).”
BackgroundSchmidt, R. W., & Thompson, M. L. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.11.266 · Cited by 16
“The NMDA-hypofunction hypothesis of schizophrenia is elegant in that antagonists (eg, phencyclidine, ketamine) at this receptor induce both positive and negative symptoms as well as cognitive deficits in healthy humans that mimic those seen in schizophrenia.(25) Glycine and related molecules function as positive allos…”
BackgroundRuljančić, N., Mihanović, M., Čepelak, I., & Bakliža, A. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12038 · Cited by 16
“The DA hypothesis is hyperactivity of dopaminergic transmission while glutamate hypothesis postulates hypofunction of glutamate Ca-permeable N-methyl-D-aspartate (NMDA) receptors.(3) Deregulation of intracellular Ca-homeostasis and signaling are involved in the pathogenesis of schizophrenia.”
BackgroundTidswell, J., Kleinig, T. J., Ash, D., Thompson, P. D., & Galletly, C. A. (2013) · Australasian Psychiatry · doi:10.1177/1039856213506502 · Cited by 18
Bitanihirwe, B. K. Y., Dubroqua, S., Singer, P., Feldon, J., & Yee, B. K. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.10.021 · Cited by 16
“This is of relevance to the hypothesized dysfunction of these neurotransmitter systems in the pathology of schizophrenia [14,15,20,22,54,60] and might therefore suggest that attentional deficits and loss of PPI in schizophrenia patients may be mediated via common glutamatergic and/or cholinergic mechanisms.”
BackgroundMaramattom, B. V., & Jacob, A. (2011) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.85872 · Cited by 17
“The combination of these heteromers leads to a receptor with complex functions, the overactivity of which leads to epilepsy, strokes and dementia, and the underactivity putatively causes schizophrenia.[6,7] Moreover, the use of NMDA antagonists such as Ketamine or PCP [phencyclidine/ “angel dust”] in individuals produ…”
BackgroundSensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit
Gray, L. J., McOmish, C. E., Scarr, E., Dean, B., & Hannan, A. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709009961 · Cited by 19
“Glutamatergic dysfunction is thought to be a key aspect underlying the aetiology of several psychiatric disorders, in particular schizophrenia (Coyle, 2006 ; Konradi & Heckers, 2003 ; Krystal et al. 2003 ; Moghaddam, 2003; Tamminga, 1998).”
BackgroundSmith, C. C., Martin, S. C., Sugunan, K., Russek, S. J., Gibbs, T. T., & Farb, D. H. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094128 · Cited by 18
“PregS might act to reduce cognitive dysfunction in schizophrenia by reducing NMDAR hypofunction (Millan, 2005; Coyle, 2006; Rujescu et al., 2006; Javitt, 2007) and activating CREB phosphorylation, a transcription factor critical in the maintenance of LTP (Bourtchuladze et al., 1994; Ahmed and Frey,…”
BackgroundMahmood, D. (2016) · International Journal of Health Sciences · doi:10.12816/0048906 · Cited by 25
Pelov, I., Teltsh, O., Greenbaum, L., Rigbi, A., Kanyas, K., Lerer, B., Lombroso, P. J., & Kohn, Y. (2012) · Psychiatric Genetics · doi:10.1097/ypg.0b013e3283518586 · Cited by 16
“There is considerable evidence suggesting the involvement of ionotrophic glutamate receptors in SZ (Coyle, 2006; Javitt, 2007).”
BackgroundEtiology of schizophrenia and therapeutic options.
Rubeša, G., Gudelj, L., & Kubinska, N. (2011) · PubMed · Cited by 26
Latifi, A., & Flegr, J. (2025) · Biomedicines · doi:10.3390/biomedicines13071731 · Cited by 18
Biopsychosocial Approach to Mental Health
Mahapatra, A., & Sharma, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-1203-8_5 · Cited by 17
Geerts, H., Roberts, P., Spiros, Ä., & Potkin, S. G. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568042 · Cited by 19
“Schizophrenia pathology is implemented using a hypodopaminergic cortical dopamine D1 receptor (D1R) tone (Durstewitz and Seamans, 2008), N-methyl-D-aspartate (NMDA) hypofunction (Coyle, 2006), documented by a hypocortical–hyperstriatal imbalance in metabolic imaging (Meyer-Lindenberg et al.”
BackgroundInfluentialSanderson, D. J., Lee, A., Sprengel, R., Seeburg, P. H., Harrison, P. J., & Bannerman, D. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-01925-8 · Cited by 15
Santini, A. C., Pierantoni, G. M., Gerlini, R., Iorio, R., Olabinjo, Y., Giovane, A., Domenico, M. D., & Sogos, C. (2014) · BioMed Research International · doi:10.1155/2014/234295 · Cited by 15
“It is well known that a central network in the pathology of psychiatric disorders is represented by glutamatergic signalling, through N-methyl-D-aspartic acid (NMDA) receptor [5].”
BackgroundChen, L. M., Nabulsi, N., Naganawa, M., Zasadny, K. R., Skaddan, M. B., Zhang, L., Najafzadeh, S., Lin, S.-F., Helal, C. J., Boyden, T. L., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171454 · Cited by 15
“PDE2A is concentrated within the synaptic compartments of many glutamatergic structures and thereby potentially positioned to selectively modulate the cyclic nucleotide signaling cascades regulating neurotransmission within the brain circuits involved in schizophrenia (8).”
BackgroundSociability development in mice with cell-specific deletion of the NMDA receptor NR1 subunit gene
Ferri, S. L., Pallathra, A. A., Kim, H., Dow, H. C., Raje, P., McMullen, M., Bilker, W. B., Siegel, S. J., Abel, T., & Brodkin, E. S. (2020) · Genes, Brain and Behavior · doi:10.1111/gbb.12624 · Cited by 15
“may play an important role in disorders such as autism spectrum disorder and schizophrenia.(29-44) Authors Sarah L.”
BackgroundPerinatal Hypoxia and Ischemia in Animal Models of Schizophrenia
Hefter, D., Marti, H. H., Gass, P., & Inta, D. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00106 · Cited by 16
Zangrando, J., Carvalheira, R., Labbate, G. P., de Medeiros, P. S., Longo, B. M., Melo-Thomas, L., & da Silva, R. C. B. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.09.018 · Cited by 15
Micronization of naringenin in supercritical fluid medium: In vitro and in vivo assays
de Oliveira, P. V., Sanaiotto, O., Kuhn, K. Z., Oltramari, A. R., Bortoluzzi, A. J., Lanza, M., Aguiar, G. P. S., Siebel, A. M., Müller, L. G., & de Oliveira, J. V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104382 · Cited by 15
Gating in Schizophrenia: From Genes to Cognition (to Real World Function?)
BRAFF, D. L. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.01.002 · Cited by 14
Effect of the G72 (DAOA) putative risk haplotype on cognitive functions in healthy subjects
Jansen, A., Krach, S., Krug, A., Markov, V., Eggermann, T., Zerres, K., Thimm, M., Nöthen, M. M., Treutlein, J., Rietschel, M., et al. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-60 · Cited by 15
Yang, C., Wang, H.-A., Tsai, T., Fan, A. P., Hsu, C., Chen, C., Hong, C., & Chen, Y. A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.12.007 · Cited by 16
“Several molecular genetic studies showed that dysregulation of the neuregulin 1 (Nrg1)-ErbB pathway and downregulation of the N-methyl-d-aspartic acid (NMDA) receptor are involved in the pathogenesis of schizophrenia (Coyle, 2006; Harrison and Law, 2006; Hahn et al., 2006).”
BackgroundLü, C.-W., Lin, T., Chang, C.-Y., Huang, S.-K., & Wang, S. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.01.017 · Cited by 15
Schizophrenia: What’s Arc Got to Do with It?
Managò, F., & Papaleo, F. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00181 · Cited by 15
“…et al., 1999; Frohlich and Van Horn, 2014) reproducing many behavioral alterations reminiscent of positive, negative and cognitive symptoms of schizophrenia in healthy humans and exaggerating positive and negative symptoms in patients with schizophrenia (Coyle, 2006; Kantrowitz and Javitt, 2010).”
Electrochemical Analysis of Antipsychotics
Karadurmuş, L., Kır, D., Kurbanoğlu, S., & Özkan, S. A. (2018) · Current Pharmaceutical Analysis · doi:10.2174/1573412914666180710114458 · Cited by 14
Kumari, V., Ettinger, U., Lee, S. E., Deuschl, C., Anilkumar, A. P., Schmechtig, A., Corr, P. J., Ffytche, D. H., & Williams, S. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3959-1 · Cited by 15
“…is a complex neurobiological disorder thought to arise from a dysregulation of multiple neurotransmitters including the dopaminergic, glutamatergic and serotonergic systems (Coyle 2006; Davis et al. 1991; Geyer and Vollenweider 2008; Howes and Kapur 2009; Javitt and Zukin 1991; van Rossum 1966).”
BackgroundIshikawa, Y., Ikeda, K., Murata, K., Hirayama, T., Takazawa, T., Yanagihashi, M., Kano, O., Kawabe, K., Takahashi, Y., & Iwasaki, Y. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.1065 · Cited by 15
“Overactivity of NMDARs causing excitotoxicity is an underlying mechanism of epilepsy, dementia and stroke whereas these hypoactivity induces neuropsychiatric symptoms of schizophrenia (17-19).”
BackgroundTspyl2 Loss-of-Function Causes Neurodevelopmental Brain and Behavior Abnormalities in Mice
Li, Q., Chan, S. Y., Wong, K.-K., Wei, R., Leung, Y. O., Ding, A. Y., Hui, T. C. K., Cheung, C., Chua, S. E., Sham, P. C., et al. (2016) · Behavior Genetics · doi:10.1007/s10519-015-9777-8 · Cited by 14
“1995), and indeed the importance of glutamate systems in the pathophysiology of schizophrenia (Coyle 2006), autism (Lee et al.”
BackgroundFlavins and Flavoproteins: Applications in Medicine
Jortzik, E., Wang, L., Ma, J., & Becker, K. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0452-5_7 · Cited by 16
Panov, G., Dyulgerova, S., Panova, P., & Stefanova, S. (2024) · Biomedicines · doi:10.3390/biomedicines12112646 · Cited by 14
IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
Moran, P. M., & Granger, K. T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107727 · Cited by 13
Molecular Genetic Models Related to Schizophrenia and Psychotic Illness: Heuristics and Challenges
O’Tuathaigh, C. M. P., Desbonnet, L., Moran, P. M., Kirby, B. P., & Waddington, J. L. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_111 · Cited by 13
Kimoto, S., Hashimoto, T., Berry, K. J., Tsubomoto, M., Yamaguchi, Y., Enwright, J. F., Chen, K., Kawabata, R., Kikuchi, M., Kishimoto, T., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01274-9 · Cited by 14
“In individuals with SZ, multiple postmortem studies have revealed structural and molecular alterations in cellular components that regulate the excitatory synaptic transmission required for WM performance [8, 9].”
BackgroundDaya, R. P., Bhandari, J., Hui, P., Tian, Y., Farncombe, T. H., & Mishra, R. K. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.10.001 · Cited by 14
Yang, J., Guo, H., Sun, D., Duan, J., Rao, X., Xu, F., Manyande, A., Tang, Y., Wang, J., & Wang, F. (2019) · PubMed · Cited by 15
Pinna, A., Serra, M., Marongiu, J., & Morelli, M. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.023 · Cited by 13
Kim, Q., Conus, P., & Cuénod, M. (2010) · Lifestyle Genomics · doi:10.1159/000324366 · Cited by 16
Decreased Serum Glutamate Levels in Male Adults with Internet Gaming Disorder: A Pilot Study
Paik, S.-H., Choi, M., Kwak, S. M., Bang, S. H., & Kim, D. (2018) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2018.16.3.276 · Cited by 13
Minocycline, schizophrenia and GluR1 glutamate receptors
Manev, R. M., & Manev, H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.004 · Cited by 13
Spiros, Ä., Roberts, P., & Geerts, H. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.12.006 · Cited by 13
Cieślik, P., & Wierońska, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228811 · Cited by 12
“, hippocampal–cortical or thalamocortical projections) [25,26].”
Background
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.